NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Fortrea Holdings Inc. (NASDAQ: FTRE). Shareholders who purchased shares of FTRE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/fortrea-holdings-inc-loss-submission-form/?id=156711&from=3 CLASS PERIOD: Ju ...

NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Petco Health and Wellness Company, Inc. (NASDAQ: WOOF). Shareholders who purchased shares of WOOF during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/petco-loss-submission-form/?id=156710&from=3  CLASS PERIOD ...

NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). Shareholders who purchased shares of SRPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/sarepta-loss-submission-form/?id=156709&from=3 CLASS PERIOD: June 22, 2 ...

Core Viewpoint - The Schall Law Firm is investigating Gilead Sciences, Inc. for potential violations of securities laws related to misleading statements and undisclosed information regarding its HIV treatment trials [1][2]. Group 1: Investigation Details - The investigation centers on whether Gilead issued false or misleading statements or failed to disclose critical information to investors [2]. - On June 10, 2025, Gilead announced that the U.S. FDA placed a clinical hold on its HIV treatment trials for GS-1720 and GS-4182 due to safety concerns, specifically a decrease in CD4+ T-cell and absolute lymphocyte counts in some trial participants [2]. Group 2: Legal Representation - The Schall Law Firm offers free consultations for shareholders who may have suffered losses and encourages them to reach out for assistance [3]. - The firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [3].

There’s a great deal you can learn about one of America’s most valuable and beloved companies from a lawsuit about pants. 🔗 https://t.co/HGvRP6jGVw https://t.co/qFpILLEPWY ...

Core Viewpoint - Investors have until July 22, 2025, to file lead plaintiff applications in securities class action lawsuits against Organon & Co. for failing to disclose material information during the class period from November 3, 2022, to April 30, 2025 [1][3] Company Information - Organon & Co. is facing lawsuits for allegedly violating federal securities laws by not disclosing important information during the specified class period [3] - The company announced a significant reduction in its dividend payout from $0.28 to $0.02 on March 10, 2025, which contradicted previous assurances to investors about maintaining the dividend [4] Financial Impact - Following the announcement of the dividend cut, Organon's share price dropped over 27%, from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025 [4] Legal Proceedings - The first filed case is Hauser v. Organon & Co., et al., No. 25-cv-05322, with a subsequent case, Lerner v. Organon & Co., et al., No. 25-cv-12983, expanding the class period [5]

Core Viewpoint - A class action lawsuit has been filed against Centene Corporation for allegedly providing misleading information regarding its expected revenue and earnings during the Class Period from December 12, 2024, to June 30, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Centene's management provided investors with overly positive statements about enrollment and morbidity rates while concealing adverse facts about the company's true performance [5]. - Investors who purchased Centene common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Process - Interested investors can join the class action by submitting a form or contacting the Rosen Law Firm for more information [3][6]. - A lead plaintiff must be appointed by September 8, 2025, to represent the class in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions for investors [4].

Core Viewpoint - A class action lawsuit has been filed against Fortrea Holdings Inc. for allegedly misleading investors regarding its financial performance and projections following its spin-off from Labcorp Holdings Inc. [1][3][5] Group 1: Company Background - Fortrea Holdings was spun off from Labcorp Holdings in June 2023 as a standalone publicly traded company [3] - The company entered into transition services agreements with Labcorp to receive various administrative and IT support services [3] Group 2: Financial Performance - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA projections for 2025 were not meeting prior expectations, leading to a significant stock price drop of $3.47 per share, or 25.05%, closing at $10.38 [4] - The company indicated that its Pre-Spin projects were underperforming, with less revenue and profitability than anticipated for 2025 [4] Group 3: Allegations in the Lawsuit - The complaint alleges that Fortrea overestimated revenue contributions from Pre-Spin projects and overstated potential cost savings from exiting transition services agreements [5] - It is claimed that the company's previously announced EBITDA targets for 2025 were inflated, misrepresenting the viability of its post-Spin-Off business model [5]

Core Viewpoint - A class action lawsuit has been filed against UroGen Pharma Ltd. for alleged misleading statements regarding its lead product UGN-102, which is intended to treat low-grade intermediate risk non-muscle invasive bladder cancer [1][2][3]. Company Overview - UroGen Pharma Ltd. focuses on developing and commercializing solutions for specialty cancers, with its primary product being UGN-102, an intravesical solution for bladder cancer treatment [2]. Allegations in the Lawsuit - The lawsuit claims that UroGen made false statements and failed to disclose critical information about the ENVISION clinical study for UGN-102, including: - The study was not designed to provide substantial evidence of effectiveness due to the absence of a concurrent control arm [3]. - UroGen faced challenges in demonstrating that the duration of response was attributable to UGN-102 [3]. - The company ignored FDA warnings regarding the study design for the new drug application (NDA) [3]. - There was a significant risk that the NDA for UGN-102 would not receive approval [3]. Impact of FDA Findings - On May 16, 2025, the FDA released a briefing document indicating concerns about the ENVISION study's design, stating that the primary endpoints were difficult to interpret due to the lack of a concurrent control arm. This led to a nearly 26% drop in UroGen's stock price [4]. - Following the FDA's Oncologic Drugs Advisory Committee vote against the NDA for UGN-102 on May 21, 2025, citing unfavorable benefit-risk assessment, UroGen's stock price fell nearly 45% [5].

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Red Cat (RCAT) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Red Cat between March 18, 2022 and January 15, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockhol ...